Literature DB >> 26573387

Bromocriptine mitigated paliperidone metabolic and neuro-hormonal side effects and improved negative domain in a case of early onset schizophrenia.

Ahmed Naguy1, Ali Al-Tajali2.   

Abstract

We report a case of early onset schizophrenia that responded favourably to paliperidone but experienced hyperprolactinaemia, tremors, and weight gain, with impaired fasting glycaemia. Addition of bromocriptine helped with both hyperprolactinaemia and tremors, but also brought about euglycaemia and, strikingly, ameliorated negative symptoms.

Entities:  

Keywords:  Bromocriptine; Hyperprolactinaemia; Metabolic syndrome; Negative domain; Paliperidone; Schizophrenia.

Mesh:

Substances:

Year:  2015        PMID: 26573387     DOI: 10.3109/08039488.2015.1094127

Source DB:  PubMed          Journal:  Nord J Psychiatry        ISSN: 0803-9488            Impact factor:   2.202


  3 in total

1.  Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia.

Authors:  Zachary Freyberg; Despoina Aslanoglou; Ripal Shah; Jacob S Ballon
Journal:  Front Neurosci       Date:  2017-07-28       Impact factor: 4.677

2.  A Comment on "Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia".

Authors:  Ahmed Naguy
Journal:  Indian J Psychol Med       Date:  2018 May-Jun

3.  Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine.

Authors:  Despoina Aslanoglou; Suzanne Bertera; Laura Friggeri; Marta Sánchez-Soto; Jeongkyung Lee; Xiangning Xue; Ryan W Logan; J Robert Lane; Vijay K Yechoor; Peter J McCormick; Jens Meiler; R Benjamin Free; David R Sibley; Rita Bottino; Zachary Freyberg
Journal:  iScience       Date:  2022-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.